title: [Embolization and degradation of arteries in vivo by pingyangmycin albumin microspheres].
abstract: OBJECTIVE
  To investigate the embolization effect of Pingyangmycin-albumin microspheres (PYM-AMS) on small arteries and its process of degradation in vivo.
  
  
  METHODS
  Twenty four Japanese white rabbits were randomly divided into four groups, 6 in each group. PYM hydrochloride + 0.9% NaCl, PYM + soybean oil, and PYM-AMS + soybean oil were injected into the central auricular arteries of the rabbits in the three experimental groups, respectively, for about 30 seconds (0.26 mL/per ear, which contained PYM 5 mg/mL). The vessel samples were taken and examined at 2, 7, 14, and 21 days.
  
  
  RESULTS
  The PYM + 0.9% NaCl group had no significant vessel changes. In the PYM+ soybean oil group, some endothelial cells dropped off at the 7th day after injection. At the 21st day, mild proliferation of endothelial cells and walls of central auricular arteries were observed, especially on the intima. But the lumen was still obvious and the blood flow was not blocked. In the PYM-AMS group, the central auricular arteries were narrowed at the 7th day after injection. At the 21st day, the vessels had sclerostenosis, and the blood flow was blocked. At the 14th day, significant proliferation of endothelial cells and walls of central auricular arteries were observed. The surface of PYM-AMS was absorbed. At the 21st day, the walls of central auricular arteries and some small veins proliferated obviously, and the arteries were sclerostenosed. Many smooth muscle cells, fibroblasts, and myofibroblasts in the original blood vessel lumen appeared. There were thrombi besides the PYM-AMS.
  
  
  CONCLUSIONS
  PYM-AMS may become an option for the treatment of large venous or arteriovenous malformations and for the local chemotherapy of malignant tumors.
authors.affiliation: Laboratory of Oral Diseases, Department of Head and Neck Oncology, West China Stomatological Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Li-li
authors.initials: LL
authors.lastname: Wang
authors.forename: Qing-hong
authors.initials: QH
authors.lastname: Gao
authors.forename: Gen-jian
authors.initials: GJ
authors.lastname: Zheng
authors.forename: Xiao-yi
authors.initials: XY
authors.lastname: Wang
authors.forename: Lan
authors.initials: L
authors.lastname: Zhou
authors.forename: Chang-mei
authors.initials: CM
authors.lastname: Wang
authors.forename: Yu-ming
authors.initials: YM
authors.lastname: Wen
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D042783:Endothelial Cells / Q000187:drug effects* / Q000473:pathology; D005260:Female; D008297:Male; D008863:Microspheres; D011817:Rabbits; D011897:Random Allocation; D012710:Serum Albumin, Bovine / Q000737:chemistry
chemical_list: D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; D012710:Serum Albumin, Bovine; C025703:bleomycetin